Chinese, U.S. Researchers Isolate Ovarian Cancer Bio-Markers
This article was originally published in PharmAsia News
Researchers from mainland China and Taiwan working with U.S. colleagues say they were able to identify bio-markers in ovarian tumors that might lead to improvements in current cancer treatment. Previous work had identified cancer stem cells in several tumor types, including brain and breast cancer, but the multinational research team has now located them in ovarian tumor tissues. Two bio-markers, CD44 and CD117, were identified as specific only to ovarian cancer cells. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.